Medicus Pharma Ltd美国招股说明书（2026年3月6日版）

PROSPECTUS SUPPLEMENT NO. 22(to prospectus dated April 10, 2025) Medicus Pharma Ltd. 1,115,500 Common Shares Issuable upon the Exercise of Warrants This prospectus supplement amends and supplements the prospectus dated effective April 10, 2025, as supplemented or amended fromtime to time (the "Prospectus"), which forms a part of our Registration Statement on Form S-1 (Registration Statement No. 333-279771). This prospectus supplement is being filed to update and supplement the information included or incorporated by reference inthe Prospectus with the information contained in our Current Report on Form 8-K, filed with the Securities and Exchange Commission This prospectus supplement updates and supplements the information in the Prospectus and is not complete without, and may not bedelivered or utilized except in combination with, the Prospectus, including any amendments or supplements thereto. This prospectussupplement should be read in conjunction with the Prospectus and if there is any inconsistency between the information in the Our common shares and warrants, with an exercise price of $4.64 and expiration date of November 15, 2029 (the "Public Warrants"),are listed on The Nasdaq Capital Market ("Nasdaq") under the symbols "MDCX" and "MDCXW," respectively. On March 5, 2026, the We are an "emerging growth company" under applicable Securities and Exchange Commission rules and are eligible forreduced public company disclosure requirements. Investing in our securities involves a high degree of risk. You should review carefully the risks and uncertainties describedunder the heading "Risk Factors" beginning on page 10 of the Prospectus, and under similar headings in any amendment orsupplements to the Prospectus. None of the Securities and Exchange Commission, any state securities commission or the securities commission of anyCanadian province or territory has approved or disapproved of the securities offered by this prospectus supplement or the The date of this prospectus supplement is March 6, 2026. UNITED STATES Washington, D.C. 20549___________________________ FORM 8-K CURRENT REPORTPursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported):March 5, 2026 MEDICUS PHARMA LTD. (Exact name of registrant as specified in its charter) 001-42408(Commission 98-1778211(IRS EmployerIdentification No.) Registrant’s telephone number, including area code:(610) 540-7515 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrantunder any of the following provisions: ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Title of each class Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b -2 of this chapter). If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Item 3.02 Unregistered Sales of Equity Securities. Pursuant to the previously disclosed Standby Equity Purchase Agreement (the "SEPA"), dated February 10, 2025, betweenMedicus Pharma Ltd. (the "Company") and YA II PN, Ltd. ("Yorkville"), the Company completed sales of its common shares (the"Common Shares") to Yorkville (collectively, the "SEPA Advances") as disclosed in the table below: The Company may cause Yorkville to purchase additional Common Shares under the SEPA from time to time, subject to thesatisfaction or waiver of the conditions and limitations set forth in the SEPA. The Company has used part of the net proceeds from theSEPA Advances to prepay a portion of the debenture the Company has outstanding with Yorkville, as described in that certain CurrentReport on Form 8-K dated September 18, 2025. The Common Shares were issued and sold to Yorkville in reliance upon the exemption This report shall not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of these securitiesin any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the Item 9.01.Financial Statements and Exhibits. (d) Exhibits. Forward Looking Statements This Current Report on Form 8-K contains forward-looking statements within the meaning of Section 27A of the Securities Act of1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation ReformAct of 1995, as amended. S